Graybug Vision
Latest round
- Series C
Last raised
- Jul 2019
Total raised
- $79M
Investors
- 8
About Graybug Vision
Founded in 2011 and based in California, US, Graybug Vision, Inc. is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of ocular diseases such as glaucoma and corneal graft rejection. The company offers GB-102, a clinical-stage depot formulation for the treatment of wet age0-related degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).
Who invested in Graybug Vision
8 investors across 4 rounds
See all investors in Graybug Vision
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Graybug Vision
Who invested in Graybug Vision?
Graybug Vision has 8 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Graybug Vision raised?
Graybug Vision has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Graybug Vision last raise money?
Graybug Vision's most recent round on record is a Series C, in Jul 2019.
What does Graybug Vision do?
Founded in 2011 and based in California, US, Graybug Vision, Inc.
Where is Graybug Vision headquartered?
Graybug Vision is headquartered in Redwood City, US.
Which VCs invest in companies like Graybug Vision?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Graybug Vision's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Graybug Vision? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.